|
|
Preclinical and clinical studies on cancer-associated cachexia |
D. Brooke Widner1, D. Clark Files2, Kathryn E. Weaver3, Yusuke Shiozawa1() |
1. Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA 2. Internal Medicine-Sections in Pulmonary and Critical Care Medicine and Geriatrics and the Critical Illness Injury and Recovery Research Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA 3. Department of Social Sciences and Health Policy and Comprehensive Cancer Center of Wake Forest University, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA |
|
|
Abstract BACKGROUND: Cancer cachexia is the wasting condition that is often seen in advanced stage cancer patients. This wasting is largely attributable to a systemic and progressive loss of skeletal muscle mass that greatly hinders performance of normal daily activities, resulting in reduced quality of life. Moreover, it negatively influences the prognosis of cancer patients. A general consensus in the field is that the loss of muscle mass is due both to an increase in protein degradation and a decrease in protein synthesis. Recent studies using preclinical models for studying cachexia have been useful in identifying the contribution of inflammatory cytokines (e.g. tumor necrosis factor-α and Interleukin-6), and myostatin receptors (e.g. the type IIB activin receptor) to cachexia development, and have led to several clinical trials. However, many questions remain about the molecular mechanisms thought to play a role in the development of cachexia. METHODS: We conducted a literature search using search engines, such as PubMed and Google Scholar to identify publications within the cancer cachexia field. RESULTS: We summarized our current knowledge of: 1) the driving mechanisms of cancer cachexia, 2) the preclinical models available for studying the condition, and 3) the findings of recent clinical trials. CONCLUSION: Cancer cachexia is a complex and variable condition that currently has no standard effective therapeutic treatment. Further studies are desperately needed to better understand this condition and develop effective combination treatments for patients.
|
Keywords
cancer cachexia
muscle wasting
bodyweight loss
metabolic changes
increased protein degradation
decreased protein synthesis
|
Corresponding Author(s):
Yusuke Shiozawa
|
Just Accepted Date: 12 February 2018
Online First Date: 15 March 2018
Issue Date: 26 March 2018
|
|
1 |
Al-Majid S, Waters H (2008). The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs, 10(1): 7–20
https://doi.org/10.1177/1099800408317345
pmid: 18705151
|
2 |
Argilés J M, Busquets S, Stemmler B, López-Soriano F J (2014). Cancer cachexia: understanding the molecular basis. Nat Rev Cancer, 14(11): 754–762
https://doi.org/10.1038/nrc3829
pmid: 25291291
|
3 |
Aulino P, Berardi E, Cardillo V M, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini E P, Baldi A, Faiola F, Adamo S, Coletti D (2010). Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer, 10(1): 363
https://doi.org/10.1186/1471-2407-10-363
pmid: 20615237
|
4 |
Bayliss T J, Smith J T, Schuster M, Dragnev K H, Rigas J R (2011). A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther, 11(12): 1663–1668
https://doi.org/10.1517/14712598.2011.627850
pmid: 21995322
|
5 |
Bennani-Baiti N, Walsh D (2009). What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb, 39(3): 257–262
pmid: 20608345
|
6 |
Bilodeau P A, Coyne E S, Wing S S (2016). The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation. Am J Physiol Cell Physiol, 311(3): C392–C403
https://doi.org/10.1152/ajpcell.00125.2016
pmid: 27510905
|
7 |
Bing C, Taylor S, Tisdale M J, Williams G (2001). Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem, 79(5): 1004–1012
https://doi.org/10.1046/j.1471-4159.2001.00639.x
pmid: 11739612
|
8 |
Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris L G, Zimmers T A (2012). JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab, 303(3): E410–E421
https://doi.org/10.1152/ajpendo.00039.2012
pmid: 22669242
|
9 |
Bowen T S, Schuler G, Adams V (2015). Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle, 6(3): 197–207
https://doi.org/10.1002/jcsm.12043
pmid: 26401465
|
10 |
Carson J A, Baltgalvis K A (2010). Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev, 38(4): 168–176
https://doi.org/10.1097/JES.0b013e3181f44f11
pmid: 20871233
|
11 |
Choi E, Carruthers K, Zhang L, Thomas N, Battaglino R A, Morse L R, Widrick J J (2013). Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep, 1(6): e00144
https://doi.org/10.1002/phy2.144
pmid: 24400146
|
12 |
Consul N, Guo X, Coker C, Lopez-Pintado S, Hibshoosh H, Zhao B, Kalinsky K, Acharyya S (2016). Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study. Clin Med Insights Oncol, 10: 83–94
https://doi.org/10.4137/CMO.S40479
pmid: 27660506
|
13 |
Crawford J, Prado C M, Johnston M A, Gralla R J, Taylor R P, Hancock M L, Dalton J T (2016). Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep, 18(6): 37
https://doi.org/10.1007/s11912-016-0522-0
pmid: 27138015
|
14 |
Deboer M D (2009). Animal models of anorexia and cachexia. Expert Opin Drug Discov, 4(11): 1145–1155
https://doi.org/10.1517/17460440903300842
pmid: 20160874
|
15 |
Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura L A (2012). Management of Anorexia-Cachexia in Late Stage Lung Cancer Patients. J Hosp Palliat Nurs, 14(6): 397–402
https://doi.org/10.1097/NJH.0b013e31825f3470
pmid: 24273460
|
16 |
Dobs A S, Boccia R V, Croot C C, Gabrail N Y, Dalton J T, Hancock M L, Johnston M A, Steiner M S (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol, 14(4): 335–345
https://doi.org/10.1016/S1470-2045(13)70055-X
pmid: 23499390
|
17 |
Eley H L, Russell S T, Tisdale M J (2007). Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J, 407(1): 113–120
https://doi.org/10.1042/BJ20070651
pmid: 17623010
|
18 |
Fearon K, Strasser F, Anker S D, Bosaeus I, Bruera E, Fainsinger R L, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos V E (2011). Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 12(5): 489–495
https://doi.org/10.1016/S1470-2045(10)70218-7
pmid: 21296615
|
19 |
Fukawa T, Yan-Jiang B C, Min-Wen J C, Jun-Hao E T, Huang D, Qian C N, Ong P, Li Z, Chen S, Mak S Y, Lim W J, Kanayama H O, Mohan R E, Wang R R, Lai J H, Chua C, Ong H S, Tan K K, Ho Y S, Tan I B, Teh B T, Shyh-Chang N (2016). Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med, 22(6): 666–671
https://doi.org/10.1038/nm.4093
pmid: 27135739
|
20 |
Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, Nemecek R, Rogowski W, Lesniewski-Kmak K, Petruzelka L, Apte R N, Mohanty P, Stecher M, Simard J, de Gramont A (2017). MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 18(2): 192–201
https://doi.org/10.1016/S1470-2045(17)30006-2
pmid: 28094194
|
21 |
Islam-Ali B, Khan S, Price S A, Tisdale M J (2001). Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br J Cancer, 85(5): 758–763
https://doi.org/10.1054/bjoc.2001.1992
pmid: 11531264
|
22 |
Jatoi A, Dakhil S R, Nguyen P L, Sloan J A, Kugler J W, Rowland K M Jr, Soori G S, Wender D B, Fitch T R, Novotny P J, Loprinzi C L (2007). A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer, 110(6): 1396–1403
https://doi.org/10.1002/cncr.22944
pmid: 17674351
|
23 |
Karayiannakis A J, Syrigos K N, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K (2001). Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res, 21(2B): 1355–1358
pmid: 11396212
|
24 |
Li Y P, Reid M B (2000). NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol, 279(4): R1165–R1170
https://doi.org/10.1152/ajpregu.2000.279.4.R1165
pmid: 11003979
|
25 |
Lok C (2015). Cachexia: The last illness. Nature, 528(7581): 182–183
https://doi.org/10.1038/528182a
pmid: 26659165
|
26 |
Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, Riccobon A, Derni S, Pallotti G, Amadori D (1997). Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer, 5(2): 130–135
https://doi.org/10.1007/BF01262570
pmid: 9069613
|
27 |
McLean J B, Moylan J S, Andrade F H (2014). Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 myotubes. Front Physiol, 5: 503
https://doi.org/10.3389/fphys.2014.00503
pmid: 25566096
|
28 |
Monitto C L, Dong S M, Jen J, Sidransky D (2004). Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res, 10(17): 5862–5869
https://doi.org/10.1158/1078-0432.CCR-04-0435
pmid: 15355918
|
29 |
Mueller T C, Bachmann J, Prokopchuk O, Friess H, Martignoni M E (2016). Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans? BMC Cancer, 16(1): 75
https://doi.org/10.1186/s12885-016-2121-8
pmid: 26856534
|
30 |
Na Y J, Baek H S, Ahn S M, Shin H J, Chang I S, Hwang J S (2007). [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol, 74(5): 780–786
https://doi.org/10.1016/j.bcp.2007.05.028
pmid: 17658483
|
31 |
Narsale A A, Carson J A (2014). Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care, 8(4): 321–327
https://doi.org/10.1097/SPC.0000000000000091
pmid: 25319274
|
32 |
National Cancer Institute (2011). Tackling the Conundrum of Cachexia in Cancer. Accessed in 2018, from .
|
33 |
Onesti J K, Guttridge D C (2014). Inflammation based regulation of cancer cachexia. BioMed Res Int, 2014: 168407
https://doi.org/10.1155/2014/168407
pmid: 24877061
|
34 |
Pagan J, Seto T, Pagano M, Cittadini A (2013). Role of the ubiquitin proteasome system in the heart. Circ Res, 112(7): 1046–1058
https://doi.org/10.1161/CIRCRESAHA.112.300521
pmid: 23538275
|
35 |
Pasut A, Jones A E, Rudnicki M A (2013). Isolation and culture of individual myofibers and their satellite cells from adult skeletal muscle. J Vis Exp, (73): e50074
pmid: 23542587
|
36 |
Patel H J, Patel B M (2017). TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci, 170: 56–63
https://doi.org/10.1016/j.lfs.2016.11.033
pmid: 27919820
|
37 |
Penafuerte C A, Gagnon B, Sirois J, Murphy J, MacDonald N, Tremblay M L (2016). Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br J Cancer, 114(6): 680–687
https://doi.org/10.1038/bjc.2016.3
pmid: 26954714
|
38 |
Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G, Zechner R, Wagner E F (2014). A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab, 20(3): 433–447
https://doi.org/10.1016/j.cmet.2014.06.011
pmid: 25043816
|
39 |
Petruzzelli M, Wagner E F (2016). Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev, 30(5): 489–501
https://doi.org/10.1101/gad.276733.115
pmid: 26944676
|
40 |
Porporato P E (2016). Understanding cachexia as a cancer metabolism syndrome. Oncogenesis, 5(2): e200
https://doi.org/10.1038/oncsis.2016.3
pmid: 26900952
|
41 |
Puppa M, Narsale A, Rose-John S, Carson J (2014). Trans IL-6 signaling and suppressed muscle protein synthesis with cancer. FASEB J, 28(1)
|
42 |
Russell S T, Sanders P M, Tisdale M J (2006). Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett, 231(2): 290–294
https://doi.org/10.1016/j.canlet.2005.02.007
pmid: 16399230
|
43 |
Sakuma K, Yamaguchi A (2012). Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle, 3(2): 77–94
https://doi.org/10.1007/s13539-011-0052-4
pmid: 22476916
|
44 |
Sandri M (2013). Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol, 45(10): 2121–2129
https://doi.org/10.1016/j.biocel.2013.04.023
pmid: 23665154
|
45 |
Shiono M, Huang K, Downey R J, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk A C, Inoue A, Halmos B, Acharyya S (2016). An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Med, 5(9): 2641–2648
https://doi.org/10.1002/cam4.841
pmid: 27485414
|
46 |
Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A (2013). Cancer cachexia--pathophysiology and management. J Gastroenterol, 48(5): 574–594
https://doi.org/10.1007/s00535-013-0787-0
pmid: 23512346
|
47 |
Temel J S, Abernethy A P, Currow D C, Friend J, Duus E M, Yan Y, Fearon K C (2016). Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol, 17(4): 519–531
https://doi.org/10.1016/S1470-2045(15)00558-6
pmid: 26906526
|
48 |
Waning D L, Mohammad K S, Reiken S, Xie W, Andersson D C, John S, Chiechi A, Wright L E, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi M S, Witzmann F A, Zhen G, Wang X, Cao X, Roodman G D, Marks A R, Guise T A (2015). Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med, 21(11): 1262–1271
https://doi.org/10.1038/nm.3961
pmid: 26457758
|
49 |
Wieland B M, Stewart G D, Skipworth R J, Sangster K, Fearon K C, Ross J A, Reiman T J, Easaw J, Mourtzakis M, Kumar V, Pak B J, Calder K, Filippatos G, Kremastinos D T, Palcic M, Baracos V E (2007). Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res, 13(17): 4984–4992
https://doi.org/10.1158/1078-0432.CCR-07-0946
pmid: 17785548
|
50 |
Winbanks C E, Murphy K T, Bernardo B C, Qian H, Liu Y, Sepulveda P V, Beyer C, Hagg A, Thomson R E, Chen J L, Walton K L, Loveland K L, McMullen J R, Rodgers B D, Harrison C A, Lynch G S, Gregorevic P (2016). Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Sci Transl Med, 8(348): 348ra98
https://doi.org/10.1126/scitranslmed.aac4976
pmid: 27440729
|
51 |
Wu C, Fernandez S A, Criswell T, Chidiac T A, Guttridge D, Villalona-Calero M, Bekaii-Saab T S (2013). Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas, 42(5): 813–818
https://doi.org/10.1097/MPA.0b013e318279b87f
pmid: 23429495
|
52 |
Yoshida T, Galvez S, Tiwari S, Rezk B M, Semprun-Prieto L, Higashi Y, Sukhanov S, Yablonka-Reuveni Z, Delafontaine P (2013). Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem, 288(33): 23823–23832
https://doi.org/10.1074/jbc.M112.449074
pmid: 23831688
|
53 |
Zhou X, Wang J L, Lu J, Song Y, Kwak K S, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet W S, Lacey D L, Goldberg A L, Han H Q (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell, 142(4): 531–543
https://doi.org/10.1016/j.cell.2010.07.011
pmid: 20723755
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|